Neuland Labs Q1FY27 Earnings Call Transcript Released
Neuland Laboratories Limited released its Q1 FY27 earnings call transcript. Total income rose 16.3% to ₹650.1 crores, with PAT at ₹147.4 crores. EBITDA was ₹231.1 crores (35.5% margin). The company expects 20% growth in FY27-FY28 and announced a strategic collaboration with Gland Pharma for sterile APIs.
The announcement includes detailed financial performance for the quarter, strategic business updates, and forward-looking guidance on growth, along with a significant new collaboration, all of which are material for investors.
The company reported significant year-on-year growth in income and profit, improved working capital efficiency, and detailed strategic growth initiatives including a collaboration with Gland Pharma. Management expressed confidence in future growth prospects.
Neuland Laboratories Limited has released the transcript of its Q1 FY27 earnings conference call, which was conducted on August 5, 2026. The call featured insights from CEO and Managing Director Mr. Saharsh Davuluri, CFO Mr. Abhijit Majumdar, and Head of Corporate Planning and Strategy Mr. Sajeev Medikonda, with moderation by Ms. Runjhun Jain from E&Y.
During the call, Mr. Abhijit Majumdar reported that total income for Q1 FY27 was ₹650.1 crores, a 16.3% increase compared to ₹300.6 crores in the corresponding quarter of the previous year. This growth was primarily driven by commercial CMS projects. EBITDA stood at ₹231.1 crores with a margin of 35.5%, and Profit After Tax was ₹147.4 crores, a significant increase from ₹13.7 crores in Q1 FY26. Working capital efficiency improved, with days reducing from 137 to 84. Capital expenditure for the quarter was ₹121.6 crores, mainly for R&D and peptide facilities. The company also approved future investments of approximately ₹203 crores for strategic growth initiatives, including capacity expansion.
Mr. Saharsh Davuluri highlighted positive performance in both GDS and CMS businesses. Key GDS contributors included Ezetimibe, Mirtazapine, Escitalopram, and Aripiprazole. The CMS business saw strong engagement with customers, with an increasing focus on becoming a long-term strategic partner. He emphasized the company's accelerated investment pace over the last three years, particularly in manufacturing infrastructure, R&D, peptides, and sterile APIs, with a long-term perspective. A strategic collaboration with Gland Pharma was also announced, aimed at creating a differentiated platform in sterile APIs by combining complementary strengths.
Management reiterated that while the business has inherent unevenness, FY27 and FY28 are expected to be years of growth, aligning with long-term ambitions. They expressed confidence in the company's medium-term trajectory due to customer interest, ongoing opportunities, and investments made. The company anticipates growth of about 20% for FY27 and FY28. The peptide plant is expected to be commissioned next month, with manufacturing qualification to follow. The strategic collaboration with Gland Pharma is an asset-light arrangement focusing on niche generic sterile APIs, leveraging Gland's sterile manufacturing capabilities and Neuland's complex API development expertise.
What to do with a filing like this
Neuland Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neuland Laboratories Limited. Read the original for the full detail.